(Q28343860)

English

Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol

scientific article

In more languages

Statements

scholarly article

0 references

Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol (English)

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

M R Goldberg

1

0 references

D Sciberras

2

0 references

M De Smet

3

0 references

R Lowry

4

0 references

L Tomasko

5

0 references

Y Lee

6

0 references

T V Olah

7

0 references

J Zhao

8

0 references

K P Vyas

9

0 references

R Halpin

10

0 references

P H Kari

11

0 references

I James

12

0 references

language of work or name

0 references

publication date

July 2001

0 references

British Journal of Clinical Pharmacology

0 references

52

0 references

1

0 references

69-76

0 references

The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014502

29 September 2017

Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014502

29 September 2017

The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014502

29 September 2017

Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014502

29 September 2017

Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014502

29 September 2017

Quantitation of the 5HT1D agonists MK-462 and sumatriptan in plasma by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014502

29 September 2017

Pilot study of MK-462 in migraine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014502

29 September 2017

Drug therapy of migraine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014502

29 September 2017

Contribution of amine oxidases to the metabolism of xenobiotics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014502

29 September 2017

Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014502

2 June 2018

Quantitative account of propranolol metabolism in urine of normal man.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014502

2 June 2018

Lack of an interaction between propranolol and sumatriptan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014502

2 June 2018

Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine.

1 reference

https://api.crossref.org/works/10.1046%2FJ.0306-5251.2001.01417.X

21 January 2018

A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11453892

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/11453892

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drug interactions and the prepared observer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11453892

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver

1 reference

https://pubmed.ncbi.nlm.nih.gov/11453892

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1046/J.0306-5251.2001.01417.X

0 references

release_hkwqdrjsibej5moxf5kranymja

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28343860&oldid=1694362372"